Keutzer Timothy's Form 4 filing
Spero Therapeutics, Inc. (SPRO) · filed Feb 5, 2026
- Accession no.
- 0001193125-26-038441
- Filed
- Feb 5, 2026
- Trade date
- Feb 2-4, 2026
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $101.2K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Keutzer TimothyCIK 0001798155 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +68,000 | $0.00 | $0 | 807,744 | Direct | |
| Feb 2, 2026 | Common Stock | SSaleDisposed | −18,891 | $2.20 | −$41,560.2 | 788,853 | Direct | |
| Feb 3, 2026 | Common Stock | SSaleDisposed | −24,224 | $2.14 | −$51,839.36 | 764,629 | Direct | |
| Feb 4, 2026 | Common Stock | SSaleDisposed | −3,471 | $2.24 | −$7,775.04 | 761,158 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Common Stock | AGrant or awardAcquired | +137,000 | $0.00 | $0 | 137,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.